Exelixis, Inc. $EXEL Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lowered its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 3.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 104,136 shares of the biotechnology company’s stock after selling 3,338 shares during the period. Nisa Investment Advisors LLC’s holdings in Exelixis were worth $4,590,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Fuller & Thaler Asset Management Inc. boosted its stake in Exelixis by 2.2% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company’s stock worth $287,794,000 after purchasing an additional 164,134 shares during the period. AQR Capital Management LLC boosted its stake in Exelixis by 73.8% during the 1st quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after purchasing an additional 2,926,884 shares during the period. Invesco Ltd. lifted its stake in shares of Exelixis by 40.2% in the 1st quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after acquiring an additional 1,596,948 shares during the period. Nuveen LLC acquired a new stake in shares of Exelixis in the 1st quarter worth $123,310,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Exelixis by 2.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,321,407 shares of the biotechnology company’s stock worth $122,626,000 after acquiring an additional 69,054 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Up 0.2%

Shares of EXEL opened at $40.08 on Wednesday. The company has a 50-day simple moving average of $38.77 and a 200-day simple moving average of $40.19. The company has a market capitalization of $10.79 billion, a PE ratio of 19.27, a P/E/G ratio of 0.80 and a beta of 0.38. Exelixis, Inc. has a 52-week low of $28.30 and a 52-week high of $49.62.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.12. The business had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business’s revenue was down 10.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.84 EPS. On average, research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analysts Forecast Growth

EXEL has been the subject of several recent analyst reports. The Goldman Sachs Group initiated coverage on shares of Exelixis in a research note on Wednesday, September 17th. They issued a “buy” rating and a $47.00 target price for the company. Leerink Partnrs upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 21st. William Blair restated an “outperform” rating on shares of Exelixis in a research note on Tuesday, July 29th. Weiss Ratings restated a “buy (b)” rating on shares of Exelixis in a research note on Wednesday, October 8th. Finally, JMP Securities restated a “market outperform” rating and issued a $50.00 target price on shares of Exelixis in a research note on Tuesday, July 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, Exelixis currently has a consensus rating of “Moderate Buy” and an average target price of $44.53.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.